ENCISION INC: insider trades · United States · SEC (Form 4)

About ENCISION INC

Encision Inc. (ticker ECIA) is a U.S.-based medical device company headquartered in Boulder, Colorado, United States. For international investors, it should be viewed as a small-cap/microcap healthcare name whose securities have been associated with the U.S. public equity market framework, with the company historically quoted on the OTC Bulletin Board rather than a major exchange. Encision was founded in 1991 by Roger Odell and Dave Newton with a focused mission: make laparoscopic surgery safer by addressing the well-documented risk of unintended patient burns caused by insulation failure and capacitive coupling in monopolar electrosurgery. The company’s core business is the design, development, manufacture and marketing of patented surgical instruments and related protection systems for minimally invasive surgery. Its defining technology is Active Electrode Monitoring (AEM®), which is intended to detect and help prevent stray electrosurgical energy from reaching the patient. Encision’s product set includes premium laparoscopic monopolar surgical instruments, the AEM EndoShield® burn protection system, the AEM Shield™ instrument family, and complementary products designed to improve clinical performance and operating-room safety. The company positions these offerings around three themes that matter to hospital buyers: patient safety, surgical performance and value. In competitive terms, Encision operates in a niche segment rather than as a broad-based medical technology platform. Its differentiation is rooted in product safety claims and patented monitoring/shielding functionality, which may appeal to hospitals and surgical teams seeking to reduce avoidable complications during minimally invasive procedures. The company has also emphasized third-party validation and institutional purchasing recognition, which can be important in medtech adoption cycles where clinician preference and procurement committee approval both influence demand. Geographically, Encision’s sales have been primarily in the United States, with additional historical sales in Australia and New Zealand. That footprint suggests a company with a domestic core market and limited but tangible international reach. From a commercial standpoint, the business is concentrated in laparoscopic and electrosurgical instruments, making it highly specialized and relatively easy to understand, but also dependent on a narrow set of use cases and customer budgets. Recent developments are important for investors. Encision reported fiscal 2025 results in 2025, with modest revenue levels and an improved gross margin trend in the latest quarter reported, reflecting some operational progress. In August 2025, the company also announced a $500,000 private placement of common stock. Most notably, in January 2026 Encision announced its intention to deregister its common stock and suspend SEC reporting obligations, a strategically significant step that changes the visibility and investability of the name. For French-speaking investors evaluating U.S. healthcare microcaps, Encision remains a highly specialized safety-oriented medtech company with a differentiated technology base, limited scale, and elevated execution risk.